Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > SEDI (System for Electronic Disclosures by Insiders)
View:
Post by Proboscises on Jan 08, 2023 11:59pm

SEDI (System for Electronic Disclosures by Insiders)

SEDI (sedi.ca) is the place to go to find insider disclosures in detail.  Access public filings and then select "View Summary Reports". You can input the name of the insider, the period of the insider transactions, and select for Common Shares and Options and you will get details of every insider transaction.  It's painstaking, but you can input the name of everyone in ONC management and every member of the BOD and you will find precice transaction detail for every one of them.

Of management you will learn:
1. Matt Coffey has 96,333 common shares and 1,354,631 options
2. Kirk Look has 45,028 common shares and 815,262 options
3. Thomas Heineman has 11,000 commonshares and 425,000 options
4. Andrew de Guttadauro has 10,315 common shares and 563,157 options
5. Allison Hagerman has 4,200 common shares and 507,683 options

Of the Board of Directors you will learn:
1. Wayne Pisano has 189,941 common shares and 83,420 options
2. Deborah Brown has 48,948 common shares and 65,263 options
3. Bernd Seizinger has 314,863 common shares and 65,263 options
4. Angela Holtham has 124,238 common shares and 65,263 options
5. James Parsons has 45,000 options
6. Jonathan Rigby has 45,000 options

What is clear is that all the members of management and the BOD have a great deal to gain from a decent buyout price or partnership deal.
Comment by canadafan on Jan 09, 2023 12:12am
Thanks fo4 the clarification Proboisius As well as great appreciation from shares, the two newest board members have 45,000 options each. quite an incentive to get the pric3 up. Iintersting Bernard has the most shares.  A buyout at a good price will make them all well off. Again certainly not zero as some folks on sites have said. remember fo4 options to be of any value, the strike ...more  
Comment by westcoast1000 on Jan 09, 2023 1:34am
I just looked up Bernd Seizinger. He got a PhD from the Max Plank institute and has been a faculty member at Harvard and Princeton for various periods, while serving as a CEO a few times and being a member of many boards for biotechs. This guy is very impressive. He also owns the most shares outright of the management and board. Of course, he is probably among the wealthiest of that group.  ...more  
Comment by westcoast1000 on Jan 09, 2023 1:52am
While this list is encouraging, this message also makes me want to buy more shares. Yikes!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities